SG183316A1 - Antigen binding proteins specific for serum amyloid p component - Google Patents

Antigen binding proteins specific for serum amyloid p component Download PDF

Info

Publication number
SG183316A1
SG183316A1 SG2012060216A SG2012060216A SG183316A1 SG 183316 A1 SG183316 A1 SG 183316A1 SG 2012060216 A SG2012060216 A SG 2012060216A SG 2012060216 A SG2012060216 A SG 2012060216A SG 183316 A1 SG183316 A1 SG 183316A1
Authority
SG
Singapore
Prior art keywords
sap
seq
antigen binding
binding protein
human
Prior art date
Application number
SG2012060216A
Other languages
English (en)
Inventor
Tejinder Kaur Bhinder
Susannah Karen Ford
Volker Germaschewski
Alan Peter Lewis
Mark Brian Pepys
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43881068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG183316(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SG183316A1 publication Critical patent/SG183316A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG2012060216A 2010-03-03 2011-03-01 Antigen binding proteins specific for serum amyloid p component SG183316A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30995710P 2010-03-03 2010-03-03
PCT/EP2011/053038 WO2011107480A1 (en) 2010-03-03 2011-03-01 Antigen binding proteins specific for serum amyloid p component

Publications (1)

Publication Number Publication Date
SG183316A1 true SG183316A1 (en) 2012-09-27

Family

ID=43881068

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012060216A SG183316A1 (en) 2010-03-03 2011-03-01 Antigen binding proteins specific for serum amyloid p component
SG10201500382SA SG10201500382SA (en) 2010-03-03 2011-03-01 Antigen binding proteins specific for serum amyloid p component

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201500382SA SG10201500382SA (en) 2010-03-03 2011-03-01 Antigen binding proteins specific for serum amyloid p component

Country Status (39)

Country Link
EP (2) EP3025729B1 (enExample)
JP (2) JP5922592B2 (enExample)
KR (1) KR101817265B1 (enExample)
CN (1) CN102858371B (enExample)
AR (1) AR080432A1 (enExample)
AU (1) AU2011223048C1 (enExample)
BR (1) BR112012021926A2 (enExample)
CA (1) CA2789557A1 (enExample)
CL (1) CL2012002418A1 (enExample)
CO (1) CO6602134A2 (enExample)
CR (1) CR20120491A (enExample)
CY (2) CY1118046T1 (enExample)
DK (2) DK2542261T3 (enExample)
DO (1) DOP2012000232A (enExample)
EA (1) EA026375B1 (enExample)
ES (2) ES2593454T3 (enExample)
HR (2) HRP20161096T1 (enExample)
HU (1) HUE028960T2 (enExample)
IL (2) IL221418A (enExample)
JO (1) JO3188B1 (enExample)
LT (2) LT3025729T (enExample)
MA (1) MA34135B1 (enExample)
ME (1) ME02491B (enExample)
MX (1) MX340350B (enExample)
MY (1) MY159255A (enExample)
NZ (1) NZ601763A (enExample)
PE (1) PE20130040A1 (enExample)
PH (1) PH12012501743A1 (enExample)
PL (2) PL2542261T3 (enExample)
PT (2) PT3025729T (enExample)
RS (2) RS57708B1 (enExample)
SG (2) SG183316A1 (enExample)
SI (2) SI2542261T1 (enExample)
SM (2) SMT201800633T1 (enExample)
TW (1) TWI558409B (enExample)
UA (1) UA108227C2 (enExample)
UY (1) UY33258A (enExample)
WO (1) WO2011107480A1 (enExample)
ZA (1) ZA201206529B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3040276A1 (en) * 2009-12-02 2011-06-09 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
WO2014100740A1 (en) * 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
CN103239713A (zh) * 2013-05-28 2013-08-14 东南大学 一种糖尿病肾病微炎症小鼠模型的建立方法
US9737505B2 (en) * 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201407506D0 (en) 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
WO2019185502A1 (en) 2018-03-26 2019-10-03 Glaxosmithkline Intellectual Property Development Limited Antibodies comprising methionine sulfoxide at the ch2-ch3 interface
CN116925216B (zh) * 2022-04-11 2024-09-24 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
EE9900343A (et) 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
ES2182203T3 (es) 1997-10-31 2003-03-01 Hoffmann La Roche Derivados de d-prolina.
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
US6903129B2 (en) 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
JP4922560B2 (ja) 2002-12-23 2012-04-25 ウイリアム、マーシュ、ライス、ユーニヴァーサティ 線維細胞への分化の検出方法、線維症を抑制する組成物および方法
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7553819B2 (en) 2003-05-12 2009-06-30 Theracarb Inc. Multivalent inhibitors of serum amyloid P component
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
WO2009155962A1 (en) * 2008-06-27 2009-12-30 Pentraxin Therapeutics Limited Use

Also Published As

Publication number Publication date
DK3025729T3 (en) 2018-11-26
MX2012010129A (es) 2012-09-12
SI3025729T1 (sl) 2018-11-30
HRP20181666T1 (hr) 2018-12-14
AU2011223048B2 (en) 2013-12-19
ES2699078T3 (es) 2019-02-07
NZ601763A (en) 2014-08-29
CY1120803T1 (el) 2019-12-11
IL251031A0 (en) 2017-04-30
EP3025729A1 (en) 2016-06-01
CR20120491A (es) 2013-02-20
PL3025729T3 (pl) 2019-02-28
ES2593454T3 (es) 2016-12-09
EA026375B1 (ru) 2017-04-28
TW201143789A (en) 2011-12-16
PH12012501743A1 (en) 2012-11-12
IL251031A (en) 2017-11-30
JO3188B1 (ar) 2018-03-08
UY33258A (es) 2011-09-30
PT3025729T (pt) 2018-11-30
MY159255A (en) 2016-12-30
CL2012002418A1 (es) 2013-03-08
JP5922592B2 (ja) 2016-05-24
DK2542261T3 (en) 2016-09-19
EA201290671A1 (ru) 2013-05-30
PE20130040A1 (es) 2013-02-09
CO6602134A2 (es) 2013-01-18
SMT201800633T1 (it) 2019-01-11
KR101817265B1 (ko) 2018-01-10
HUE028960T2 (en) 2017-01-30
LT3025729T (lt) 2018-12-10
PT2542261T (pt) 2016-09-27
SG10201500382SA (en) 2015-03-30
RS57708B1 (sr) 2018-12-31
IL221418A (en) 2017-03-30
CY1118046T1 (el) 2017-05-17
CA2789557A1 (en) 2011-09-09
JP2016154535A (ja) 2016-09-01
EP2542261B1 (en) 2016-07-06
MA34135B1 (fr) 2013-04-03
SMT201600337B (it) 2016-11-10
CN102858371B (zh) 2017-03-01
SI2542261T1 (sl) 2016-11-30
DOP2012000232A (es) 2013-01-15
HRP20161096T1 (hr) 2016-11-04
EP3025729B1 (en) 2018-09-12
BR112012021926A2 (pt) 2020-08-25
TWI558409B (zh) 2016-11-21
WO2011107480A1 (en) 2011-09-09
HK1173959A1 (zh) 2013-05-31
ME02491B (me) 2017-02-20
HK1223292A1 (en) 2017-07-28
IL221418A0 (en) 2012-10-31
AR080432A1 (es) 2012-04-11
UA108227C2 (xx) 2015-04-10
LT2542261T (lt) 2016-09-26
AU2011223048C1 (en) 2018-06-21
KR20130027483A (ko) 2013-03-15
MX340350B (es) 2016-07-06
RS55133B1 (sr) 2016-12-30
CN102858371A (zh) 2013-01-02
ZA201206529B (en) 2018-12-19
EP2542261A1 (en) 2013-01-09
JP6236478B2 (ja) 2017-11-22
PL2542261T3 (pl) 2016-12-30
JP2013521252A (ja) 2013-06-10
AU2011223048A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
AU2011223048B2 (en) Antigen binding proteins specific for serum amyloid P component
AU2011209713B2 (en) CD127 binding proteins
AU2018219595B2 (en) Anti human annexin A1 antibody
SG172039A1 (en) Myostatin binding proteins
US10221234B2 (en) Antigen binding proteins
HK1223292B (en) Antigen binding proteins specific for serum amyloid p component
CA3140071A1 (en) Anti-angpt2 antibodies
US12071481B2 (en) Anti-CD47 antibodies and uses thereof
US20240327522A1 (en) Anti-alpha v beta 8 integrin antibodies and methods of use
HK1173959B (en) Antigen binding proteins specific for serum amyloid p component